Your browser doesn't support javascript.
loading
The role of IL-38 in intestinal diseases - its potential as a therapeutic target.
Wang, Qiang; Ma, Linna; An, Caiping; Wise, Steven G; Bao, Shisan.
Afiliación
  • Wang Q; Department of Anatomy, School of Basic Medicine, Gansu University of Chinese Medicine, Lanzhou, Gansu, China.
  • Ma L; Department of Pathology, School of Basic Medicine, Gansu University of Chinese Medicine, Lanzhou, Gansu, China.
  • An C; Department of Haematology and Nephropathy, Gansu Provincial Hospital, Lanzhou, Gansu, China.
  • Wise SG; School of Medical Sciences, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.
  • Bao S; Department of Anatomy, School of Basic Medicine, Gansu University of Chinese Medicine, Lanzhou, Gansu, China.
Front Immunol ; 13: 1051787, 2022.
Article en En | MEDLINE | ID: mdl-36405715
IL-38, an anti-inflammatory cytokine, is a key regulator of homeostasis in host immunity. Intestinal immunity plays a critical role in defence against pathogenic invasion, as it is the largest surface organ and the most common entry point for micro-organisms. Dysregulated IL-38 activity is observed in several autoimmune diseases including systemic lupus erythematosus and atherosclerosis. The protective role of IL-38 is well illustrated in experimental colitis models, showing significantly worse colitis in IL-38 deficient mice, compared to wildtype mice. Moreover, exogenous IL-38 has been shown to ameliorate experimental colitis. Surprisingly, upregulated IL-38 is detected in inflamed tissue from inflammatory bowel disease patients, consistent with increased circulating cytokine levels, demonstrating the complex nature of host immunity in vivo. However, colonic IL-38 is significantly reduced in malignant tissues from patients with colorectal cancer (CRC), compared to adjacent non-cancerous tissue. Additionally, IL-38 expression in CRC correlates with 5-year survival, tumour size and differentiation, suggesting IL-38 plays a protective role during the development of CRC. IL-38 is also an independent biomarker for the prognosis of CRC, offering useful information in the management of CRC. Taken together, these data demonstrate the role of IL-38 in the maintenance of normal intestinal mucosal homeostasis, but that dysregulation of IL-38 contributes to initiation of chronic inflammatory bowel disease (resulting from persistent local inflammation), and that IL-38 provides protection during the development of colorectal cancer. Such data provide useful information for the development of novel therapeutic targets in the management of intestinal diseases for more precise medicine.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Colorrectales / Enfermedades Inflamatorias del Intestino / Colitis Límite: Animals Idioma: En Revista: Front Immunol Año: 2022 Tipo del documento: Article País de afiliación: China Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Colorrectales / Enfermedades Inflamatorias del Intestino / Colitis Límite: Animals Idioma: En Revista: Front Immunol Año: 2022 Tipo del documento: Article País de afiliación: China Pais de publicación: Suiza